News for PTC Therapeutics, Inc. (PTCT)

The FDA decision on PharmaTher Holdings' resubmitted Abbreviated New Drug Application for racemic ketamine KETARX is due on August 9, 2025..

PR NewswireWARREN, N.J., July 21, 2025 WARREN, N.J., July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company w

PTC Therapeutics (PTCT) to discuss Q2 2025 financial results on August 7, 4:30 p.m. ET. Participants are encouraged to register early and join 15 minute

July is observed as Sarcoma Awareness Month. Sarcoma is a rare type of cancer that affects muscles, fat, nerves, and other connective tissues. As we get ready to welcome July, it's also time to track the important FDA decisions lined up for the month.

PTC Therapeutics (PTCT) has secured marketing approval from the European Commission for its drug Sephience, aimed at treating phenylketonuria (PKU) in both pedi

PR NewswireWARREN, N.J., June 23, 2025 ”“ Broad label inclusive of all ages and disease severities ”“ ”“ Launch to be initiated in Germany ”“WARREN, N

PR NewswireNEW YORK, June 22, 2025 NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics

Summary PTC Therapeutics Inc (PTCT), a global biopharmaceutical company, announced on June 19, 2025, that it has approved non-statutory stock options and restri

PR NewswireWARREN, N.J., June 19, 2025 WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

In a significant move for PTC Therapeutics (PTCT), Truist Securities has initiated coverage with a "Buy" rating. The prominent financial analysis firm, represen

PR NewswireNEW YORK, June 17, 2025 NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics

PTC Therapeutics (PTCT) has received a Buy rating from Truist, with a price target set at $80. The company is preparing for the potential launch of two new drug

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therap

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics,

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (”œPTC” or the ”œCompan

RBC Capital's analyst, Brian Abrahams, has increased the price target for PTC Therapeutics (PTCT) from $58 to $60, while maintaining an Outperform rating for th